Recent patents in allergy and immunology: Method for treating asthma or allergic disease via anti-Notch4 mAb.

Allergy

Division of Immunology, Department of Pediatrics, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.

Published: July 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694330PMC
http://dx.doi.org/10.1111/all.15317DOI Listing

Publication Analysis

Top Keywords

patents allergy
4
allergy immunology
4
immunology method
4
method treating
4
treating asthma
4
asthma allergic
4
allergic disease
4
disease anti-notch4
4
anti-notch4 mab
4
patents
1

Similar Publications

Polyunsaturated fatty acids (PUFAs), fatty acids with multiple unsaturated carbon-carbon bonds, constitute a crucial class of lipids. While the vast diversity of PUFA species arises from their structural variations, most of them are poorly investigated due to their limited availability. Here, we utilize solid-phase synthesis of PUFAs, which we have recently developed, to construct a PUFA library.

View Article and Find Full Text PDF

Role of hydrogen sulfide in catalyzing the formation of NO-ferroheme.

Nitric Oxide

September 2025

Department of Physics, Wake Forest University, Winston-Salem, NC, 27109, USA; Translational Science Center, Wake Forest University, Winston-Salem, NC, 27109, USA. Electronic address:

We recently demonstrated a rapid reaction between labile ferric heme and nitric oxide (NO) in the presence of reduced glutathione (GSH) or other small thiols in a process called thiol-catalyzed reductive nitrosylation, yielding a novel signaling molecule, labile nitrosyl ferrous heme (NO-ferroheme), which we and others have shown can regulate vasodilation and platelet homeostasis. Red blood cells (RBCs) contain high concentrations of GSH, and NO can be generated in the RBC via nitrite reduction and/or RBC endothelial nitric oxide synthase (eNOS) so that NO-ferroheme could, in principle, be formed in the RBC. NO-ferroheme may also form in other cells and compartments, including in plasma, where another small and reactive thiol species, hydrogen sulfide (HS/HS), is also present and may catalyze NO-ferroheme formation akin to GSH.

View Article and Find Full Text PDF

Background: Predictors for checkpoint inhibitor-related pneumonitis (cinrPneumonitis) are desperately needed. This study aimed to investigate the pretreatment standardized uptake value (SUV) on [F]FDG-PET/CT of non-tumorous lung tissue as a predictive imaging marker for the development of cinrPneumonitis in 239 patients with lung cancer.

Methods: All patients with lung cancer receiving [F]Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) prior to immune checkpoint inhibitor (ICI) therapy were included and retrospectively analyzed.

View Article and Find Full Text PDF

Patients in outpatient dialysis settings, including InCenter and Home Therapies, have the potential to experience hypersensitivity reactions from multiple sources, such as dialyzer membranes, other products unique to dialysis, and new medications. Awareness of co-factors, frequently present in the end stage kidney disease population, is crucial in managing reactions effectively. Dialysis staff must act quickly to identify anaphylaxis.

View Article and Find Full Text PDF